This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cabot, M. C. Articles by Liu, Y.-Y. Search for Related Content PubMed PubMed Citation Articles by Cabot, M. C. Articles by Liu, Y.-Y.

SDZ PSC 833, the Cyclosporine A Analogue and Multidrug Resistance Modulator, Activates Ceramide Synthesis and Increases Vinblastine Sensitivity in Drug-sensitive and Drug-resistant Cancer Cells¹

John Wayne Cancer Institute, Saint John’s Health Center, Santa Monica, California 90404

Resistance to chemotherapy is the major cause of cancer treatment failure. Insight into the mechanism of action of agents that modulate multidrug resistance (MDR) is instrumental for the design of more effective treatment modalities. Here we show, using KB-V-1 MDR human epidermoid carcinoma cells and [³H]palmitic acid as metabolic tracer, that the MDR modulator SDZ PSC 833 (PSC 833) activates ceramide synthesis. In a short time course experiment, ceramide was generated as early as 15 min (40% increase) after the addition of PSC 833 (5.0 µM), and by 3 h, [³H]ceramide was >3-fold that of control cells. A 24-h dose-response experiment showed that at 1.0 and 10 µM PSC 833, ceramide levels were 2.5- and 13.6-fold higher, respectively, than in untreated cells. Concomitant with the increase in cellular ceramide was a progressive decrease in cell survival, suggesting that ceramide elicited a cytotoxic response. Analysis of DNA in cells treated with PSC 833 showed oligonucleosomal DNA fragmentation, characteristic of apoptosis. The inclusion of fumonisin B₁, a ceramide synthase inhibitor, blocked PSC 833-induced ceramide generation. Assessment of ceramide mass by TLC lipid charring confirmed that PSC 833 markedly enhanced ceramide synthesis, not only in KB-V-1 cells but also in wild-type KB-3–1 cells. The capacity of PSC 833 to reverse drug resistance was demonstrated with vinblastine. Whereas each agent at a concentration of 1.0 µM reduced cell survival by 20%, when PSC 833 and vinblastine were coadministered, cell viability fell to zero. In parallel experiments measuring ceramide metabolism, it was shown that the PSC 833/vinblastine combination synergistically increased cellular ceramide levels. Vinblastine toxicity, also intensified by PSC 833 in wild-type KB-3-1 cells, was as well accompanied by enhanced ceramide formation. These data demonstrate that PSC 833 has mechanisms of action in addition to P-glycoprotein chemotherapy efflux pumping.

This article has been cited by other articles:

				W. D. Meacham, J. W. Antoon, M. E. Burow, A. P. Struckhoff, and B. S. Beckman Sphingolipids as Determinants of Apoptosis and Chemoresistance in the MCF-7 Cell Model System Experimental Biology and Medicine, November 1, 2009; 234(11): 1253 - 1263. [Abstract] [Full Text] [PDF]

				L. Hong, Y. Piao, Y. Han, J. Wang, X. Zhang, Y. Du, S. Cao, T. Qiao, Z. Chen, and D. Fan Zinc ribbon domain-containing 1 (ZNRD1) mediates multidrug resistance of leukemia cells through regulation of P-glycoprotein and Bcl-2 Mol. Cancer Ther., December 1, 2005; 4(12): 1936 - 1942. [Abstract] [Full Text] [PDF]

				J. Kankesan, R. Vanama, A. Yusuf, J. J. Thiessen, V. Ling, P. M. Rao, S. Rajalakshmi, and D. S.R. Sarma Effect of PSC 833, an inhibitor of P-glycoprotein on N-methyl-N-nitrosourea induced mammary carcinogenesis in rats Carcinogenesis, March 1, 2004; 25(3): 425 - 430. [Abstract] [Full Text] [PDF]

				J. Kankesan, A. Yusuf, E. Laconi, R. Vanama, G. Bradley, J. J. Thiessen, V. Ling, P. M. Rao, S. Rajalakshmi, and D. S. R. Sarma Effect of PSC 833, an inhibitor of P-glycoprotein, on 1,2-dimethylhydrazine-induced liver carcinogenesis in rats Carcinogenesis, December 1, 2003; 24(12): 1977 - 1984. [Abstract] [Full Text] [PDF]

				I. Plo, G. Lehne, K. J. Beckstrom, N. Maestre, A. Bettaieb, G. Laurent, and D. Lautier Influence of Ceramide Metabolism on P-Glycoprotein Function in Immature Acute Myeloid Leukemia KG1a Cells Mol. Pharmacol., August 1, 2002; 62(2): 304 - 312. [Abstract] [Full Text] [PDF]

				H. Wang, A. E. Giuliano, and M. C. Cabot Enhanced de Novo Ceramide Generation through Activation of Serine Palmitoyltransferase by the P-Glycoprotein Antagonist SDZ PSC 833 in Breast Cancer Cells Mol. Cancer Ther., July 1, 2002; 1(9): 719 - 726. [Abstract] [Full Text] [PDF]

				G. S. Watts, B. W. Futscher, R. Isett, M. Gleason-Guzman, M. W. Kunkel, and S. E. Salmon cDNA Microarray Analysis of Multidrug Resistance: Doxorubicin Selection Produces Multiple Defects in Apoptosis Signaling Pathways J. Pharmacol. Exp. Ther., November 1, 2001; 299(2): 434 - 441. [Abstract] [Full Text] [PDF]

				G. Laurent and J.-P. Jaffrezou Signaling pathways activated by daunorubicin Blood, August 15, 2001; 98(4): 913 - 924. [Abstract] [Full Text] [PDF]

				M. Baekelandt, G. Lehne, C. G. Trope, I. Szanto, P. Pfeiffer, B. Gustavssson, and G. B. Kristensen Phase I/II Trial of the Multidrug-Resistance Modulator Valspodar Combined With Cisplatin and Doxorubicin in Refractory Ovarian Cancer J. Clin. Oncol., June 15, 2001; 19(12): 2983 - 2993. [Abstract] [Full Text] [PDF]

				A. Senchenkov, D. A. Litvak, and M. C. Cabot Targeting Ceramide Metabolism--a Strategy for Overcoming Drug Resistance J Natl Cancer Inst, March 7, 2001; 93(5): 347 - 357. [Abstract] [Full Text] [PDF]

				Y.-Y. LIU, T.-Y. HAN, A. E. GIULIANO, and M. C. CABOT Ceramide glycosylation potentiates cellular multidrug resistance FASEB J, March 1, 2001; 15(3): 719 - 730. [Abstract] [Full Text] [PDF]

				M. Selzner, A. Bielawska, M. A. Morse, H. A. Rüdiger, D. Sindram, Y. A. Hannun, and P.-A. Clavien Induction of Apoptotic Cell Death and Prevention of Tumor Growth by Ceramide Analogues in Metastatic Human Colon Cancer Cancer Res., February 1, 2001; 61(3): 1233 - 1240. [Abstract] [Full Text]